Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04360-4
Abstract: SF3B1 is a highly mutated gene in myelodysplastic syndrome (MDS) patients, related to a specific subtype and parameters of good prognosis in MDS without excess blasts. More than 40% of MDS patients carry at least… read more here.
Keywords: biological prognostic; clinical biological; mds patients; mds ... See more keywords
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0118-9
Abstract: Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb ≤ 10.0 g/dL, with… read more here.
Keywords: risk; placebo controlled; low risk; placebo ... See more keywords
Genetic mutations associated with blood count abnormalities in myeloid neoplasms
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2022.2094134
Abstract: ABSTRACT Introduction Myelodysplastic syndromes (MDS) predominantly present with varying degrees of cytopenia, while myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) exhibit proliferative features. Genetic defects underlying different complete blood count (CBC) alterations remain to be defined. Objective We… read more here.
Keywords: mds; mds mpn; risk mds; blood ... See more keywords
Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-199032
Abstract: Background Myelodysplastic neoplasms (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are hematologic malignancies characterized by dysfunctional hematopoiesis. These disorders frequently exhibit upregulation of inflammatory pathways, particularly those involving interleukin-1β (IL-1β) and interleukin-1 receptor-associated kinase 4 (IRAK4) within… read more here.
Keywords: treatment; hematopoiesis; lucas canfire; irak4 ... See more keywords
Bone Marrow-Derived CD57+ NK and NK-like T-Cells Expand in Lower-Risk MDS and Are Implicated in Driving Bone Marrow Failure
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210271
Abstract: Background: Myelodysplastic syndromes (MDS) are marked by clonally expanded hematopoietic stem cells (HSC), impaired hematopoiesis, and concurrent cytopenia(s). Hematopoietic dysfunction and bone marrow (BM) failure (BMF) are the leading causes of morbidity and mortality in… read more here.
Keywords: mds pts; mds; cell; bone marrow ... See more keywords
IL-17 as a targetable pathway to reverse early NK cell dysregulation in high-risk MDS with late relapse
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2448
Abstract: Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis, high risk of leukemic transformation, and poor survival in high-risk patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially… read more here.
Keywords: relapse; cell; risk mds; high risk ... See more keywords
Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5625
Abstract: Introduction: Although hypomethylating agents (HMA) have improved outcomes in higher-risk myelodysplastic syndromes (MDS), survival remains poor, particularly for transplant ineligible patients. Anemia is a hallmark of MDS. Symptomatic anemia is associated with complications such as… read more here.
Keywords: intermediate high; risk; high risk; risk mds ... See more keywords
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007334
Abstract: Key points In the phase 3 PANTHER trial, EFS was similar between arms in the intent-to-treat population and in patients with higher-risk MDS. A signal for improved overall survival for pevonedistat+azacitidine was seen in higher-risk… read more here.
Keywords: risk mds; pevonedistat plus; higher risk; plus azacitidine ... See more keywords
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
Sign Up to like & getrecommendations! Published in 2024 at "Blood Advances"
DOI: 10.1182/bloodadvances.2023012120
Abstract: Key Points • Maintenance treatment was safe, with low rates of infections and chronic GVHD, and minimal impact on T-cell immune reconstitution.• With 2-year follow-up, Ven/Aza maintenance showed a manageable safety profile and encouraging responses… read more here.
Keywords: maintenance; high risk; mds aml; prophylactic maintenance ... See more keywords
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2025016229
Abstract: Key Points • In the phase 3 SELECT-MDS-1 trial, CR was similar between arms in pts with higher-risk MDS.• RARA gene overexpression/RARα activation in myeloid malignancies warrants further investigation as biomarker-driven studies are feasible. read more here.
Keywords: higher risk; phase; pivotal results; select mds ... See more keywords
Phase 3 study of either ivosidenib monotherapy or azacitidine monotherapy in patients with IDH1-mutant myelodysplastic syndromes who are hypomethylating agent naive (PyramIDH).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.tps6584
Abstract: TPS6584 Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid disorders that occur predominantly in older patients with variable risk of progression to acute myeloid leukemia (AML). According to International Prognostic Scoring Systems,… read more here.
Keywords: mds; risk mds; per iwg; monotherapy ... See more keywords